Company intelligence / Profile preview
Polaris Group
Zhunan, Miaoli County, Taiwanpolarispharma.com ↗
- Ownership
- Private
- Employees
- ~160
- Development stage
- Other
01
Overview
Polaris Group’s lead asset Pegargiminase ("ADI‑PEG 20", trade name ADZODI) is a biologic targeting arginine metabolism. It is in late-stage clinical development for multiple cancers. A rolling BLA submission was made to the US FDA for malignant pleural mesothelioma in November 2024. Three additional Phase III trials are ongoing for glioblastoma, leiomyosarcoma, and hepatocellular carcinoma. The company is preparing for commercialization and seeking global/regional partners. Early results suggest potential benefit as salvage therapy in BRAFi-resistant melanoma as well.
- Therapeutic areas
- GastroenterologyOncologyEndocrinology
- Modalities
- BiologicPeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MD Anderson Cancer Center—collaboration on immunotherapy platform
Beyond the preview
Go deeper on Polaris Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polaris Group.